nivolumab,ipilimumab,cabozantinib
exelixis,bms
['nivo', 'triplet,(-triplete)', 'rcc,(-irccs),(-srcc),(-urcc)']
do we have a new winner for the rcc intermediate imdc group? triplet with cabo/nivo-ipi shows pfs benefit. expecting os results. #esmo2022 
Medical Oncologist with love for Sarcomas. Putting an effort to become the Clinician scientist of my dream...